NGNE Neurogene Inc.
$36.14
Neurogene Inc. (NGNE) is expected to report earnings on November 10, 2026, after the market close. The consensus earnings estimate is a loss of $1.39 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -0.1% since its last earnings release on August 11, 2026.
Neurogene Inc. Missed Consensus Estimates
Tuesday, August 11, 2026 · 7:30 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 10
Tuesday · 4:05 PM ET
Earnings Whisper
-
vs ($1.39)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP
$36.24
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Neurogene Inc.
Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders.
Sector
Healthcare
Industry
Biotechnology